-
Dextromethorphan hydrobromide: Protocol and QC Guide for Res
2026-04-25
Dextromethorphan hydrobromide provides a controlled, well-characterized NMDA receptor antagonist for research into neuroprotection, excitotoxicity inhibition, and ion channel modulation. It is intended strictly for scientific workflows and should not be applied to diagnostic, clinical, or therapeutic uses where regulatory and safety evidence is lacking.
-
PBS Liposomes: Setting New Standards for Macrophage Depletio
2026-04-24
This thought-leadership article explores the strategic and mechanistic rationale for deploying PBS Liposomes as the benchmark control in in vivo macrophage depletion studies. By bridging insights from ion channel research and macrophage biology, the article guides translational scientists through the challenges of assay design, data reproducibility, and the evolving landscape of immunological research. Contextual references to landmark studies and existing content assets position this discussion as an advancement over traditional product pages, highlighting how rigorous controls like PBS Liposomes are essential for credible, translatable discovery.
-
Optimizing Neurodegeneration Models with Amyloid Beta-peptid
2026-04-24
This authoritative guide addresses core laboratory challenges in neurodegenerative disease research using Amyloid Beta-peptide (25-35) (human) (SKU A1039). Integrating scenario-driven Q&A, recent mechanistic literature, and workflow best practices, we demonstrate how SKU A1039 supports reproducible, data-backed cytotoxicity and microglial polarization assays. Researchers gain evidence-based insights to streamline experimental design and reliability in Alzheimer's disease modeling.
-
Optimizing Cell Viability Assays with Ganetespib (STA-9090)
2026-04-23
This article addresses common laboratory challenges in cell viability and cytotoxicity assays by providing scenario-driven solutions with Ganetespib (STA-9090), SKU A4385. By integrating quantitative benchmarks and evidence-based protocol guidance, researchers can enhance reproducibility and data quality. Practical recommendations highlight when to select Ganetespib (STA-9090) from APExBIO for robust Hsp90 inhibition.
-
Anlotinib Hydrochloride: Multi-Target TKI for Angiogenesis A
2026-04-23
Anlotinib hydrochloride stands out as a multi-target tyrosine kinase inhibitor with superior potency and selectivity for angiogenesis research. Its robust inhibition of VEGFR2, PDGFRβ, and FGFR1, coupled with low cytotoxicity, enables highly reproducible endothelial cell workflows and advanced tumor modeling.
-
iPSC-Derived Airway Models for CF Drug Testing: A Multimodal
2026-04-22
This study introduces a robust multimodal induced pluripotent stem cell (iPSC) platform to evaluate cystic fibrosis (CF) therapies, including rare CFTR variants not addressed by current modulators. By integrating adapted functional assays in iPSC-derived airway cells, the research demonstrates genotype-specific drug responses, paving the way for more inclusive and predictive preclinical approaches.
-
MAPK10 Phosphorylation Drives KRT16 Degradation in NSCLC Met
2026-04-22
This study uncovers a phosphorylation-dependent mechanism by which MAPK10 suppresses non-small cell lung cancer (NSCLC) metastasis through the ubiquitination and degradation of keratin 16. The findings offer new insight into the MAPK10/KRT16/RNF213 axis as a prognostic marker and therapeutic target, with implications for precision cancer research.
-
Co-Targeting BRD4 and RAC1 Disrupts c-MYC/G9a Axis in Breast
2026-04-21
This paper establishes that simultaneous inhibition of BRD4 and RAC1 disrupts the c-MYC/G9a/FTH1 axis, suppressing growth, stemness, and tumorigenesis in diverse breast cancer subtypes. The findings highlight epigenetic modulation as a promising strategy for targeting cancer progression and suggest new avenues for research using chemical probes such as G9a inhibitors.
-
DAPI Solution (1 mg/mL): Precision Nuclear Visualization in
2026-04-21
DAPI Solution (1 mg/mL) from APExBIO is a robust tool for high-contrast nuclear visualization, enabling reliable viability assessment and apoptosis detection in fixed or compromised cells. This guide delivers evidence-backed workflows, hands-on protocol parameters, and troubleshooting strategies that bridge innovative research findings with practical assay optimization.
-
Aminopeptidase Inhibitor Phebestin: New Antimalarial Mechani
2026-04-20
The reference study identifies phebestin, a bestatin-related aminopeptidase inhibitor, as a potent antiplasmodial agent with nanomolar activity against both drug-sensitive and resistant Plasmodium falciparum strains. Its low host cytotoxicity and efficacy in in vivo models highlight aminopeptidase inhibition as a promising therapeutic strategy for malaria.
-
MHY1485: mTOR Activator for Autophagy & Follicle Assays
2026-04-20
MHY1485 stands out as a precise mTOR activator, enabling researchers to dissect autophagy inhibition and follicle development with exceptional assay control. This guide covers experimental protocols, troubleshooting strategies, and the translational impact of MHY1485 in advanced cellular workflows.
-
Puerarin Modulates Gut Microbiota and Adipose Thermogenesis
2026-04-19
This study demonstrates that puerarin improves glucose and lipid metabolism in type 2 diabetes (T2D) mice by restoring gut microbiota balance and enhancing adipose tissue thermogenesis. These findings highlight new mechanistic insights for phytotherapeutic strategies in T2D management and suggest opportunities for translational research targeting microbiota and energy homeostasis.
-
BMS 599626 dihydrochloride: Precision EGFR and ErbB2 Inhibit
2026-04-18
BMS 599626 dihydrochloride stands out as a selective EGFR and ErbB2 inhibitor for advanced cancer and senescence research. This guide details practical workflows, experimental best practices, and troubleshooting strategies, uniquely informed by the latest machine learning-driven drug discovery insights and benchmarked protocols.
-
ER-Targeted EISA Peptides for Selective Cancer Cell Fate Mod
2026-04-17
This study introduces a peptide system engineered for enzyme-instructed self-assembly (EISA) that selectively targets the endoplasmic reticulum (ER) in cancer cells, leveraging ALP overexpression to induce ER stress and promote apoptosis and necroptosis. The findings highlight a significant advance in organelle-targeted cancer therapy, lowering effective concentrations and offering a pathway to overcome drug resistance.
-
Protease Inhibitor Cocktail (100X): Preventing Protein Degra
2026-04-16
The Protease Inhibitor Cocktail (100X in DMSO, EDTA plus) offers robust, broad-spectrum protein degradation prevention during extraction workflows. By inhibiting serine, cysteine, aspartic proteases, and aminopeptidases, this reagent ensures sample integrity for advanced applications such as Western blotting and co-immunoprecipitation.